Neostigmine is used to treat myasthenia gravis, a condition where muscles become weak and tired easily, and to reverse the effects of certain anesthesia drugs after surgery.[2] Prostigmin is currently approved and in use across 26 indications[4].[1]
Prostigmin is one of 508 small molecule programs targeting Arrhythmia. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
2828 competitors in Breast Cancer
Prostigmin
Cymbalta
MS Contin
Effexor
Spravato
Chirocaine
Feraheme
Aquasol E
Vfend
Systemic Therapy
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details